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Madam, A proto-oncogene is a normal gene that can
become an oncogene due to mutations or increased
expression. Proto-oncogene codes for proteins that assist
regulate cell growth and differentiation through
contribution in signal transduction and mitogenic signals
concert, generally do it through their protein yield.
Subsequent to attaining mutation, a proto-oncogene
turns into a tumour inducing mediator, an oncogene.
Classic proto-oncogenes are RAS, WNT, MYC, ERK. The RAS
proto-oncogene (from rat sarcoma) was one of the earliest
human oncogenes discovered and comprises at least three
different biologically active genes as H-RAS, K-RAS and N-
RAS.1 These three genes code for the G proteins present
in the plasma membrane and contribute to initiating a
cascade of protein kinases, leading to activation of nuclear
transcription factors and alteration of gene expression
mostly at positions 12, 13 and 61. Alterations in RAS genes
have been detected in a wide range of human tumours,
with a total incidence of 10% to 15%. H-RAS is generally
associated with bladder and kidney cancer, N-RAS in
melanoma and haematological malignancies and K-RAS
in gastrointestinal cancers as biliary, pancreatic, colorectal,
lung and ovarian cancers. K-RAS mutations have been
extensively so far and more than 3000 point mutations
have been reported to date.2 The most common mutations
occur in codons 12 and 13, about 80% on codon 12 and
20% on codon 13. However, cancer itself and its treatment
have a considerable psychological impression on patients
and their families appended by various corporeal,
demonstrative, mystical, social and communal upheavals.3
Cancer patients with depression have meager survival
through profound interaction between psychological and
carnal glitches. Many screening tests are introduced aiming
to distinguish cancer before the commencement of
symptoms.4 The benefits of screening are in terms of
cancer deterrence, prompt detection and post-treatment
requirement to be evaluated against impending harm.
However, subjects who have been screened for mutations
have multiple chances of becoming psychologically
vulnerable.5 It is therefore necessary to develop a profile
of mental health screening as well, particularly for
depression in patients with positive mutations evolving
cancer. Depression should be evaluated and treated as
early as possible in these patients as it is a predictor of
negative survival. Therefore, it is vital to determine and
treat depression in such subjects to guarantee better
treatment compliance and improved survival possibilities.
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